Food and Drug Administration has approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia
The drug is for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine. Vyxeos combines two commonly used chemotherapies into a single formulation that may help some patients live longer than if they were to receive the two therapies separately.
Acute myeloid leukemia AML is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of white blood cells in the bloodstream. It occurs as a complication of chemotherapy or radiation in patients treated for cancer five years after treatment.
Patients who have a history of serious hypersensitivity to daunorubicin, cytarabine or any component of the formulation should not use Vyxeos.
Patients taking Vyxeos should be monitored for hypersensitivity reactions and decreased cardiac function.
Common side effects of Vyxeos are: hemorrhage, fever with low white blood cell count, rash, swelling of the tissues, nausea, inflammation of the mucous membranes, diarrhea, constipation, musculoskeletal pain, fatigue, abdominal pain, shortness of breath, headache, cough, decreased appetite, abnormal heart rhythm, lung infection, blood infection, sleep disorders and vomiting.
haleplushearty.blogspot.com
No comments:
Post a Comment